TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (&#34;Galmed&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">TEL AVIV, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 31, 2026</span> /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) (&#34;Galmed&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the &#39;SEC&#39;). </p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" title="(PRNewsfoto/Galmed Pharmaceuticals Ltd.)" alt="(PRNewsfoto/Galmed Pharmaceuticals Ltd.)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">The report is available on the SEC&#39;s website, at <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.sec.gov/" target="_blank" rel="nofollow">www.sec.gov</a> and Galmed&#39;s Investor Relations website, at <a xmlns="http://www.w3.org/1999/xhtml" href="https://galmedpharma.investorroom.com/sec-filings" target="_blank" rel="nofollow">https://galmedpharma.investorroom.com/sec-filings</a>.</p><p xmlns="http://www.w3.org/1999/xhtml">Shareholders can obtain copies of Galmed&#39;s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed&#39;s Investor Relations Department at <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investor.relations@galmedpharma.com" target="_blank" rel="nofollow">investor.relations@galmedpharma.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">About Galmed Pharmaceuticals Ltd.</i></b></p><p xmlns="http://www.w3.org/1999/xhtml">We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver diseases, and continue to actively advance Aramchol for the treatment of combination therapy for NASH. We are also seeking to develop Aramchol for certain oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</i></b></p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential synergistic effect of Aramchol, Stivarga<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> and Metformin as a new fixed-dose combination treatment, the expected timing of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry&#39;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading &#34;Risk Factors.&#34; Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml">Logo - </span><a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/5890434/Galmed_Pharmaceuticals_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1713483/5890434/Galmed_Pharmaceuticals_Logo.jpg</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN22281&amp;sd=2026-03-31"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025-302730059.html" target="_blank">https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025-302730059.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Galmed Pharmaceuticals Ltd.</p>

GLMD

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Files Annual Report with Key Updates on Aramchol

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (&amp;#34;Galmed&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Galmed Pharmaceuticals has filed its Annual Report for FY 2025, providing updates on its key drug Aramchol and other business aspects. Investors should monitor developments regarding Aramchol’s clinical trials and potential market entry, as they may significantly affect the company&#039;s valuation and stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Galmed Pharmaceuticals filed its Annual Report on Form 20-F with the SEC.</li><li>The report covers financial results and business updates for FY 2025.</li><li>Galmed focuses on developing Aramchol for liver diseases and additional indications.</li><li>The company is pursuing expansion of its product pipeline in cardiometabolic areas.</li><li>Forward-looking statements contain risks that could affect future developments.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>U.S. Food and Drug Administration (FDA) (N/A)</strong>: FDA&#039;s regulatory decisions are crucial for Aramchol&#039;s approval and commercial success.</li><li><strong>European Medicines Authority (EMA) (N/A)</strong>: EMA&#039;s actions will also impact Galmed&#039;s European market strategy for Aramchol.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under &#039;Corporate Developments&#039; as it provides essential updates on Galmed&#039;s ongoing operational activities and pipeline progress. Such filings are crucial for investors tracking the company&#039;s strategic direction and financial health.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Approval timelines for Aramchol could drastically impact GLMD&#039;s stock price.</li><li>Any delays in clinical trials could create downward pressure on shares.</li><li>Successful data from NASH trials could attract new investment and partnerships.</li><li>Regulatory decisions on marketing applications will directly influence market perception.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Galmed filed its 2025 Annual Report on March 31, 2026.</li><li>The company&#039;s focus remains on Aramchol for liver diseases and oncological indications.</li><li>Potential risks include competition and clinical development uncertainties.</li><li>The report is available on the SEC&#039;s website and Galmed&#039;s Investor Relations page.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>GLMD is a speculative buy on potential positive developments surrounding Aramchol&#039;s trials in the next 12 months.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">TEL AVIV, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 31, 2026</span> /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) (&#34;Galmed&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the &#39;SEC&#39;). </p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" title="(PRNewsfoto/Galmed Pharmaceuticals Ltd.)" alt="(PRNewsfoto/Galmed Pharmaceuticals Ltd.)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">The report is available on the SEC&#39;s website, at <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.sec.gov/" target="_blank" rel="nofollow">www.sec.gov</a> and Galmed&#39;s Investor Relations website, at <a xmlns="http://www.w3.org/1999/xhtml" href="https://galmedpharma.investorroom.com/sec-filings" target="_blank" rel="nofollow">https://galmedpharma.investorroom.com/sec-filings</a>.</p><p xmlns="http://www.w3.org/1999/xhtml">Shareholders can obtain copies of Galmed&#39;s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed&#39;s Investor Relations Department at <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investor.relations@galmedpharma.com" target="_blank" rel="nofollow">investor.relations@galmedpharma.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">About Galmed Pharmaceuticals Ltd.</i></b></p><p xmlns="http://www.w3.org/1999/xhtml">We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver diseases, and continue to actively advance Aramchol for the treatment of combination therapy for NASH. We are also seeking to develop Aramchol for certain oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</i></b></p><p xmlns="http://www.w3.org/1999/xhtml">Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential synergistic effect of Aramchol, Stivarga<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> and Metformin as a new fixed-dose combination treatment, the expected timing of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry&#39;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading &#34;Risk Factors.&#34; Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml">Logo - </span><a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/5890434/Galmed_Pharmaceuticals_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1713483/5890434/Galmed_Pharmaceuticals_Logo.jpg</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN22281&amp;sd=2026-03-31"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025-302730059.html" target="_blank">https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2025-302730059.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Galmed Pharmaceuticals Ltd.</p>

Galmed Pharmaceuticals has filed its Annual Report for FY 2025, providing updates on its key drug Aramchol and other business aspects. Investors should monitor developments regarding Aramchol’s clinical trials and potential market entry, as they may significantly affect the company's valuation and stock performance.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News